Premium
Induction and inhibition of cicletanine metabolism in cultured hepatocytes and liver microsomes from rats
Author(s) -
Menard Christophe,
Lamiable Denis,
Vistelle Richard,
Morin Elisabeth,
Ratanasavanh Damrong
Publication year - 2000
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/j.1472-8206.2000.tb00434.x
Subject(s) - glucuronidation , chemistry , enantiomer , ugt2b7 , microsome , enzyme inducer , metabolism , pharmacology , isozyme , drug metabolism , biochemistry , enzyme , stereochemistry , biology
— Cicletanine, a racemic furopyridine derivative synthesized as racemate, is used as an antihypertensive agent. Its two enantiomers are involved in the pharmacological effects of the drug. Cicletanine is metabolized by conjugation enzyme systems (phase II) into sulfoconjugated or glucuroconjugated enantiomers. This study reports on the use of both the induction with 3‐methylcholanthrene (3‐MC) or phenobarbital (PB) and inhibition with selective compounds to determine and identify UGT isoenzymes involved in the metabolism of cicletanine enantiomers. PB and 3‐MC both enhanced the cicletanine enantiomer glucuronidation. These two compounds being known as inducing agents of UGT2B1 and UGT1A6 isoforms, respectively, this suggests an implication of UGT2B1 and UGTIA6 isoforms in the metabolism of the two cicletanine enantiomers: (+)‐cicletanine and (‐)‐cicletanine. The use of selective compounds for inhibition study evidenced, in addition to UGT2BI and UGT1A6 isoforms, the involvement of other UGT isoforms such as UGTIAI, UGT2B7 and UGT2B15 in cicletanine metabolism.